Axitinib and Survivin Vaccine Enhance PD-1 Therapy in Renal Carcinoma
Sequential treatment with axitinib followed by a survivin vaccine and PD-1 blockade leads to durable tumor control in renal carcinoma.
Asset / Drug
Drug and asset intelligence for Axitinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.